



09/505.788

January 16, 2001



chain nodes :

1 2 3 4 5 6 9 10 13

ring nodes :

7 8 11

chain bonds :

1-2 2-3 2-9 3-4 4-5 5-6 5-10 6-7 8-13

ring bonds :

7-8 8-11

exact/norm bonds :

1-2 2-9 5-6 5-10 6-7 7-8 8-11 8-13

exact bonds :

2-3 3-4 4-5

G1:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom
9:CLASS 10:CLASS 11:Atom 13:CLASS

=> d his

(FILE 'HOME' ENTERED AT 15:31:11 ON 16 JAN 2001)

FILE 'REGISTRY' ENTERED AT 15:31:23 ON 16 JAN 2001

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 50 S L2

L4 1248 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:32:18 ON 16 JAN 2001

L5 196 S L4

FILE 'REGISTRY' ENTERED AT 15:32:57 ON 16 JAN 2001

L6 696 S L4 AND 7/SZS


FILE 'CAPLUS' ENTERED AT 15:33:17 ON 16 JAN 2001

L7 14 S L6

=> d l2

L2 HAS NO ANSWERS

L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> d bib abs hitstr l7 1-14

L7 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 2000:456838 CAPLUS

DN 133:89552

TI Succinoylaminobenzodiazepines as inhibitors of A.beta. protein production

IN Olson, Richard E.

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038618	A2	20000706	WO 1999-US30815	19991223

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX,
NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ,

Applicant

MD, RU, TJ, TM
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 -PT, SE
 AU-2000020592 A5 20000731 AU 2000-20592 19991223
 PRAI US 1998-113588 19981224
 WO 1999-US30815 19991223
 OS MARPAT 133:89552
 GI




AB Succinoylaminobenzodiazepines I [R = (un)substituted NH₂; R₁ = (un)substituted alkyl; R₂, R₄ = H, OH, alkyl, alkoxy, alkenyl, alkenyloxy; R₃ = H, (un)substituted OH, alkyl, alkoxy, alkenyl, alkynyl, carbocyclic aryl, heterocyclic; R₅, R₆ = H, (un)substituted alkyl, carbocyclic, aryl; R₇ = (un)substituted ph, pyridyl] were prepd. I inhibit the processing of amyloid precursor protein and, more specifically, inhibit the prodn. of A.beta.-peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein and are useful in the treatment of neurol. disorders related to .beta.-amyloid prodn. such as Alzheimer's disease and Down's Syndrome. Thus, the title compd. II was prepd. by treating (2R, 3S)-Me₃CO₂CCH(CH₂CH:CH₂)CH(CH₂CHMe₂)CO₂H with the aminobenzodiazepine, ester hydrolysis, and amidation.

IT **280568-35-6P 280568-38-9P 280568-69-6P**
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of succinoylaminobenzodiazepines as inhibitors of A.beta.-protein prodn.)

RN 280568-35-6 CAPLUS
 CN Butanediarnide, N1-[(3S)-7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R, 3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-38-9 CAPLUS

CN Butanediamide,

N1-[(3S)-7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-69-6 CAPLUS

CN Butanediamide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 280568-36-7P 280568-39-0P 280568-43-6P

280568-44-7P 280568-70-9P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).


(prepn. of succinoylaminobenzodiazepines as inhibitors of A.beta.-protein prodn.)

RN 280568-36-7 CAPLUS

CN Butanedi-2-amine, N1-[(3R)-7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-39-0 CAPLUS

CN Butanedi-2-amine,

N1-[(3R)-7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-43-6 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-5-(4-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-44-7 CAPLUS

CN Butanedi-2-amine, N1-[(3R)-5-(4-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-70-9 CAPLUS

CN Butanedi-2-amine, N1-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 280568-27-6P 280568-29-8P 280568-32-3P

280568-65-2P 280568-75-4P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of succinoylaminobenzodiazepines as inhibitors of
 A:beta.-protein prodn.)

RN 280568-27-6 CAPLUS

CN Butanediamide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-29-8 CAPLUS

CN Butanediamide, N1-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-32-3 CAPLUS

CN Butanediamide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methyl-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-65-2 CAPLUS

CN Butanediamide, 3-(3-butenyl)-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-75-4 CAPLUS

CN Butanediamide, 3-(3-butenyl)-N1-[(3S)-5-(4-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 280568-24-3P 280568-25-4P 280568-26-5P
 280568-30-1P 280568-31-2P 280568-33-4P
 280568-34-5P 280568-40-3P 280568-41-4P
 280568-42-5P 280568-45-8P 280568-46-9P

280568-47-0P 280568-49-2P 280568-51-6P
 280568-52-7P 280568-53-8P 280568-56-1P
 280568-57-2P 280568-58-3P 280568-59-4P
 280568-60-7P 280568-61-8P 280568-62-9P
 280568-63-0P 280568-64-1P 280568-67-4P
 280568-71-0P 280568-73-2P 280568-74-3P
 280568-77-6P 280568-78-7P 280568-79-8P
 280568-82-3P 280568-84-5P 280568-86-7P
 280568-88-9P 280568-89-0P 280568-90-3P
 280568-91-4P 280568-94-7P 280568-98-1P
 280568-99-2P 280569-00-8P 280569-11-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of succinoylaminobenzodiazepines as inhibitors of A.beta.-protein prodn.)


RN 280568-24-3 CAPLUS

CN Butanediamide,

N1-[(3,5-difluorophenyl)methyl]-N4-(2,3-dihydro-1-methyl-2-

oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(2-methylpropyl)-2-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-25-4 CAPLUS

CN Butanediamide, N1-[(3S)-5-(2-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-26-5 CAPLUS

CN Butanediarnide, N1-[(3R)-5-(2-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-30-1 CAPLUS

CN Butanediarnide, N1-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-31-2 CAPLUS


CN Butanediarnide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-33-4 CAPLUS
 CN Butanediamide, N1-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-34-5 CAPLUS
 CN Butanediamide,
 N1-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280568-40-3 CAPLUS
 CN Butanediamide, N1-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3R)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-41-4 CAPLUS
 CN Butanediamide, N1-[(3S)-7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

INDEX NAME)

Absolute stereochemistry.




RN 280568-42-5 CAPLUS

CN Butanediamide,

N1-[(3S)-7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-45-8 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-1-methyl-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-46-9 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-1-methyl-5-(4-morpholinyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-47-0 CAPLUS

CN Butanediamide, N1-[5-(dimethylamino)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-49-2 CAPLUS

CN Butanediamide,
N1-[2,3-dihydro-1-methyl-5-(methylphenylamino)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-51-6 CAPLUS

CN Butanediarnide, N1-[2,3-dihydro-1-methyl-2-oxo-5-(1-piperidinyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-52-7 CAPLUS

CN Butanediarnide,
N1-[5-(hexahydro-1H-azepin-1-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-53-8 CAPLUS

CN Butanediarnide, N1-[2,3-dihydro-5-(3-methoxyphenyl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-56-1 CAPLUS

CN Butanediarnide, N1-[2,3-dihydro-1-methyl-2-oxo-5-(4-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-57-2 CAPLUS

CN Butanediarnide, N1-(2,3-dihydro-7-methoxy-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-58-3 CAPLUS

CN Butanediarnide, N1-[2,3-dihydro-1-methyl-2-oxo-5-(3-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-59-4 CAPLUS

CN Butanediarnide,
3-(cyclopropylmethyl)-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-60-7 CAPLUS

CN Butanediarnide,
3-(cyclopropylmethyl)-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-61-8 CAPLUS

CN Butanediamide, N1-[(3S)-5-(3-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-62-9 CAPLUS

CN Butanediamide, N1-[(3R)-5-(3-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-63-0 CAPLUS

CN Butanediamide,
3-(3-butenyl)-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-

1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-64-1 CAPLUS

CN Butanediamide,

3-(2-cyclopentylethyl)-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-67-4 CAPLUS

CN Butanediamide, 3-(3-butenyl)-N1-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-71-0 CAPLUS

CN Butanedi-~~am~~ide, N4-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-methylpropyl)-2,2-di-2-propenyl-, (3R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-73-2 CAPLUS

CN Butanedi-~~am~~ide, 3-butyl-N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-74-3 CAPLUS

CN Butanedi-~~am~~ide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-77-6 CAPLUS

CN Butanediamide,

3-butyl-N1-[(3S)-5-(4-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-78-7 CAPLUS

CN Butanediamide, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-N4-(phenylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-79-8 CAPLUS

CN Butanediamide, N1-(2,3-dihydro-1,5-dimethyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-82-3 CAPLUS

CN Butanediamide,

N1-(5-butyl-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-84-5 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-1-methyl-5-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280568-86-7 CAPLUS

CN Butanediamide, N1-[(3S)-5-(4-chlorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-


1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 280568-88-9 CAPLUS
CN Butanediamide, N1-[(3S)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 280568-89-0 CAPLUS
CN Butanediamide, N1-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1-propyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-90-3 CAPLUS

CN Butanediarnide, N1-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-propyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-91-4 CAPLUS

CN Butanediarnide, N1-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 280568-94-7 CAPLUS

CN Butanediarnide,
N1-(6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl)-2-
(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-98-1 CAPLUS

CN Butanedi-2,3-diamide, 2-(2-methylpropyl)-3-(2-propenyl)-N1-(2,3,4,5-tetrahydro-1,5-dimethyl-2,4-dioxo-1H-1,5-benzodiazepin-3-yl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280568-99-2 CAPLUS

CN Butanedi-2,3-diamide, 2-(2-methylpropyl)-3-(2-propenyl)-N1-(2,3,4,5-tetrahydro-1-methyl-2-oxo-1H-1-benzazepin-3-yl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280569-00-8 CAPLUS

CN Butanedi-2-amine, N1-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methyl-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280569-11-1 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methyl-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 2000:335658 CAPLUS

DN 133:779

TI Preparation and use of radioligands to screen inhibitors of .beta.-amyloid peptide production

IN Zaczek, Robert C.; Olson, Richard E.; Seiffert, Dietmar A.; Thompson, Lorin Andrew

PA Du Pont Pharmaceuticals Company, USA

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000028331	A1	20000518	WO 1999-US26715	19991112
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, SG, SK, TR, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1998-108147		19981112		


US 1999-131284 19990427
 OS MARPAT 133:779
 AB A method is provided for screening for inhibitors of .beta.-amyloid prodn., and thereby identifying such inhibitors as therapeutics for neurol. and other disorders involving amyloid precursor protein (APP) processing and beta-amyloid prodn. The invention also relates to identifying macromols. involved in APP processing and .beta.-amyloid prodn. Furthermore, inhibitors identified by the screening method of the invention are useful in the treatment of neurol. disorders, e.g. Alzheimer's disease, which involve elevated levels of A.beta. peptides. Prepn. of radioligands is described.
 IT **269056-25-9DP**, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction; radioligand prepn. for screening inhibitors of .beta.-amyloid peptide prodn.)
 RN 269056-25-9 CAPLUS
 CN Butanediamide,
 N1-[(3S)-hexahydro-1-[(3-iodophenyl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **258864-68-5P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (radioligand prepn. for screening inhibitors of .beta.-amyloid peptide prodn.)
 RN 258864-68-5 CAPLUS
 CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 258864-80-1P 269056-21-5P 269056-22-6P
269056-23-7P

RL: BPR (Biological process); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
(radioligand prepn. for screening inhibitors of .beta.-amyloid peptide
prodn.)

RN 258864-80-1 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-
azepin-3-yl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 269056-21-5 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-
azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, labeled with tritium, (2R,3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


258864-77-6P 258864-78-7P 258864-79-8P
 258866-03-4P 258870-12-1P 258870-13-2P
 258870-14-3P 258870-15-4P 258870-16-5P
 258870-17-6P 258870-19-8P 258870-21-2P
 258870-24-5P 258870-30-3P 258870-65-4P
 269056-29-3P 269056-30-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (radioligand prepn. for screening inhibitors of .beta.-amyloid peptide
 prodn.)

RN 258864-62-9 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-
 azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 258864-63-0 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-
 yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-64-1 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-
 biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-,
 (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-65-2 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-66-3 CAPLUS

CN Butanediamic acid, N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-67-4 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-70-9 CAPLUS

CN Butanediamide,
N1-[(3S)-1-[(3'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-71-0 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-72-1 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(2'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258864-74-3 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-[[5-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-75-4 CAPLUS

CN Butanediamide, N1-[(3S)-1-[[5-(3-chloro-4-fluorophenyl)-3-pyridinyl]methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-76-5 CAPLUS

CN Butanedi-2,3-diamide, N1-[(3S)-hexahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-3-(2-methylpropyl)-2-propyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-77-6 CAPLUS

CN Butanedi-2,3-diamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-(2-methylpropyl)-2-propyl-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258864-78-7 CAPLUS

CN Butanedi-2,3-diamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

(NAME)

Absolute stereochemistry.




RN 258864-79-8 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA

INDEX

(NAME)

Absolute stereochemistry.




RN 258866-03-4 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-12-1 CAPLUS

CN Butanediamide,

N1-[(3S)-1-(3,3-diphenylpropyl)hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-13-2 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-14-3 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-15-4 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-methyl-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-16-5 CAPLUS

CN Butanedi-*amide*, N1-[(3*S*)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1*H*-azepin-3-yl]-N4-methoxy-2-(2-methylpropyl)-3-propyl-, (2*R*,3*S*)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-17-6 CAPLUS

CN Butanedi-*amide*, N1-[(3*S*)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1*H*-azepin-3-yl]-N4-methoxy-2-(2-methylpropyl)-3-propyl-, (2*R*,3*S*)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-19-8 CAPLUS

CN Butanedi-*amide*, N1-[(3*S*)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1*H*-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-(2-propenyl)-, (2*R*,3*S*)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-21-2 CAPLUS

CN Butanediamide,

N1-[(3S)-1-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-24-5 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(3'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-30-3 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-65-4 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 269056-29-3 CAPLUS


CM Butanediolamide, N1-[(3S)-hexahydro-1-[[5-(4-methoxyphenyl)-3-pyridinyl]methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 258864-73-2

CMF C30 H42 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 269056-30-6 CAPLUS

CN Butanediarnide, N1-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT. 3

RE

- (1) Du Pont; WO 9200374 A 1992 CAPLUS
- (2) Knops, J; US 5538845 A 1996 CAPLUS
- (3) Scios Inc; WO 9815828 A 1998 CAPLUS

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 2000:161321 CAPLUS

DN 132:221336

TI Benzodiazepines and benzothiazepines derivatives and HBsAg peptides binding to annexins, their compositions and use

IN Depla, Erik; Moëreels, Henri; Maertens, Geert

PA Innogenetics N.V., Belg.

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012547	A2	20000309	WO 1999-EP6231	19990825
	WO 2000012547	A3	20000615		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9956247	A1	20000321	AU 1999-56247	19990825
PRAI	EP 1998-870186		19980901		
	EP 1999-870062		19990329		
	WO 1999-EP6231		19990825		

OS MARPAT 132:221336

AB The present invention relates to 1,4-benzodiazepines or 1,4-benzothiazepines derivatized with a peptide that can inhibit the interaction between annexin and annexin binding proteins. In particular, the present invention relates to 1,4-benzodiazepines or 1,4-benzothiazepines derivs. that can inhibit the interaction between

of annexin and viral proteins that bind annexins such as the HBsAg protein of HBV, glycoprotein B of the cytomegalovirus or any annexin binding protein from the influenza virus. These 1,4-benzodiazepines or 1,4-benzothiazepines derivs. can be used to prevent or treat diseases in which interactions between annexin family members and annexin binding proteins are involved such as HBV and/or HDV infections, cytomegalovirus infections or influenza virus infections.

IT **260437-36-3P 260437-37-4P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzodiazepine and benzothiazepine deriv. coupled to viral peptide for inhibiting interaction of annexin and annexin binding protein and for preventing or treating viral infection)

RN 260437-36-3 CAPLUS


CN L-Arginine, N-[4-[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl)amino]-1,4-dioxobutyl]-L-phenylalanyl-L-alanyl-L-lysyl-


L-tyrosyl-L-leucyl-L-tryptophyl-L-.alpha.-glutamyl-L-tryptophyl-L-alanyl-L-seryl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 260437-37-4 CAPLUS

CN L-Arginine, N-[4-[[1-(carboxymethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1,4-dioxobutyl]-L-phenylalanyl-L-alanyl-L-lysyl-


L-tyrosyl-L-leucyl-L-tryptophyl-L-.alpha.-glutamyl-L-tryptophyl-L-alanyl-L-seryl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




AN 2000:117029 CAPLUS
 DN 132:166134
 TI Preparation of succinoylaminoazepinones and related compounds as inhibitors of A.beta.-peptide production.
 IN Olson, Richard E.; Maduskuie, Thomas P.; Thomas, Lorin Andrew
 PA Du Pont Pharmaceuticals Co., USA
 SO PCT Int. Appl., 315 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000007995	A1	20000217	WO 1999-US17717	19990807
	W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9953378	A1	20000228	AU 1999-53378	19990807
PRAI	US 1998-95698		19980807		
	US 1998-113558		19981224		
	US 1999-120227		19990215		
	WO 1999-US17717		19990807		
OS	MARPAT 132:166134				
GI					



I



II

AB Title compds. [I; Q = OR1, NR1R2; R1 = H, (substituted) alkyl, alkenyl, carbocyclyl, aryl, heterocyclyl; R2 = H, NH2, OH, alkyl, alkoxy, PhO, PhCH2O, carbocyclyl, aryl, heterocyclyl; R3 = (CR7R7a)nR4, etc.; n = 0-3; R3a = H, OH, alkyl, alkoxy, alkenyloxy; R4 = H, OH, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl; R5 = H, OR14, (substituted) alkyl, alkoxy, alkenyl, alkynyl, carbocyclyl, aryl, heterocyclyl; R14 = H, Ph, PhCH2, alkyl, alkoxyalkyl; R5a = H, OH, alkyl, alkoxy, alkenyl, alkenyloxy; R6 = H, (substituted) alkyl, carbocyclyl, aryl; R7, R7a = H, OH, Cl, F, Br, iodo, cyano, NO2, CF3, alkyl; W = (CR8R8a)p; p = 0-4; R8, R8a = H, F, alkyl, alkenyl, alkynyl, cycloalkyl;

X

Applicant's

= bond, (substituted) aryl, carbocyclyl, heterocyclyl; Y = bond, (CR9R9a)tV(CR9R9a)u; t, u = 0-3; R9, R9a = H, F, alkyl, cycloalkyl; V = bond, CO, O, S, SO, SO₂, imino, etc.; Z = (substituted) alkyl, aryl, carbocyclyl, heterocyclyl; B = atoms to form an (unsatd.) (substituted) (heteroatom-contg.) lactam ring], were prepd. which inhibit the

processing

of amyloid precursor protein and, more specifically, inhibit the prodn.

of

A.beta.-peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein. Thus, title compd. (II) was prepd. in several steps starting with L-.alpha.-amino-.epsilon.-caprolactam. I inhibited A.beta. prodn. with IC₅₀<100 .mu.M.

IT 258864-62-9P 258864-63-0P 258864-64-1P
 258864-65-2P 258864-66-3P 258864-67-4P
 258864-68-5P 258864-69-6P 258864-70-9P
 258864-71-0P 258864-72-1P 258864-73-2P
 258864-74-3P 258864-75-4P 258864-76-5P
 258864-77-6P 258864-78-7P 258864-79-8P
 258864-80-1P 258864-81-2P 258864-82-3P
 258864-83-4P 258864-84-5P 258864-85-6P
 258864-86-7P 258864-87-8P 258864-88-9P
 258864-90-3P 258864-91-4P 258864-92-5P
 258864-93-6P 258864-94-7P 258864-95-8P
 258864-96-9P 258864-97-0P 258864-98-1P
 258864-99-2P 258865-00-8P 258865-01-9P
 258865-02-0P 258865-03-1P 258865-04-2P
 258865-05-3P 258865-06-4P 258865-07-5P
 258865-08-6P 258865-09-7P 258865-10-0P
 258865-11-1P 258865-12-2P 258865-13-3P
 258865-14-4P 258865-15-5P 258865-16-6P
 258865-17-7P 258865-18-8P 258865-19-9P
 258865-20-2P 258865-21-3P 258865-22-4P
 258865-23-5P 258865-24-6P 258865-25-7P
 258865-26-8P 258865-27-9P 258865-28-0P
 258865-29-1P 258865-30-4P 258865-31-5P
 258865-32-6P 258865-33-7P 258865-34-8P
 258865-35-9P 258865-36-0P 258865-37-1P
 258865-38-2P 258865-39-3P 258865-40-6P
 258865-41-7P 258865-42-8P 258865-43-9P
 258865-44-0P 258865-45-1P 258865-46-2P
 258865-47-3P 258865-49-5P 258865-50-8P
 258865-51-9P 258865-52-0P 258865-53-1P
 258865-54-2P 258865-55-3P 258865-56-4P
 258865-57-5P 258865-58-6P 258865-59-7P
 258865-60-0P 258865-61-1P 258865-62-2P
 258865-63-3P 258865-64-4P 258865-65-5P
 258865-66-6P 258865-67-7P 258865-68-8P
 258865-69-9P 258865-70-2P 258865-71-3P
 258865-72-4P 258865-73-5P 258865-74-6P
 258865-75-7P 258865-76-8P 258865-77-9P
 258865-78-0P 258865-79-1P 258865-80-4P
 258865-81-5P 258865-82-6P 258865-83-7P
 258865-84-8P 258865-85-9P 258865-86-0P
 258865-87-1P 258865-88-2P 258865-89-3P
 258865-90-6P 258865-91-7P 258865-92-8P
 258865-93-9P 258865-94-0P 258865-95-1P
 258865-96-2P 258865-97-3P 258865-98-4P
 258865-99-5P 258866-00-1P 258866-01-2P
 258866-02-3P 258866-03-4P 258866-04-5P

258866-05-6P 258866-06-7P 258866-07-8P
 258866-08-9P 258866-09-0P 258866-10-3P
 258866-11-4P 258866-12-5P 258866-13-6P
 258866-14-7P 258866-15-8P 258866-17-0P
 258866-18-1P 258866-19-2P 258866-20-5P
 258866-21-6P 258866-22-7P 258866-23-8P
 258866-24-9P 258866-25-0P 258866-26-1P
 258866-27-2P 258866-28-3P 258866-29-4P
 258866-30-7P 258866-31-8P 258866-32-9P
 258866-33-0P 258866-34-1P 258866-35-2P
 258866-36-3P 258866-37-4P 258866-38-5P
 258866-39-6P 258866-40-9P 258866-41-0P
 258866-42-1P 258866-43-2P 258866-44-3P
 258866-45-4P 258866-46-5P 258866-47-6P
 258866-48-7P 258866-49-8P 258866-50-1P
 258866-51-2P 258866-52-3P 258866-53-4P
 258866-54-5P 258866-55-6P 258866-56-7P
 258866-57-8P 258866-58-9P 258866-59-0P
 258866-60-3P 258866-61-4P 258866-62-5P
 258866-63-6P 258866-64-7P 258866-65-8P
 258866-66-9P 258866-67-0P 258866-68-1P
 258866-69-2P 258866-70-5P 258866-71-6P
 258866-72-7P 258866-73-8P 258866-74-9P
 258866-75-0P 258866-76-1P 258866-77-2P
 258866-78-3P 258866-79-4P 258866-80-7P
 258866-81-8P 258866-82-9P 258866-83-0P
 258866-84-1P 258866-85-2P 258866-86-3P
 258866-87-4P 258866-88-5P 258866-89-6P
 258866-90-9P 258866-91-0P 258866-92-1P
 258866-93-2P 258866-94-3P 258866-95-4P
 258866-96-5P 258866-97-6P 258866-98-7P
 258866-99-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of succinoylaminoazepinones and related compds. as inhibitors of A.beta.-peptide prodn.)

RN 258864-62-9 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.




RN 258864-63-0 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-

yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-64-1 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-65-2 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-66-3 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-67-4 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-68-5 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-69-6 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258864-70-9 CAPLUS

CN Butanediamide,

N1-[(3S)-1-[(3'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-71-0 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-72-1 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-hexahydro-1-[(2'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-73-2 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-hexahydro-1-[[5-(4-methoxyphenyl)-3-pyridinyl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258864-74-3 CAPLUS


CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-[[5-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-,

(2R,3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-75-4 CAPLUS

CN Butanediamide, N1-[(3S)-1-[[5-(3-chloro-4-fluorophenyl)-3-pyridinyl]methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-76-5 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-3-(2-methylpropyl)-2-propyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-77-6 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-(2-methylpropyl)-2-propyl-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258864-78-7 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

(NAME)

Absolute stereochemistry.




RN 258864-79-8 CAPLUS

CN Butanediamic acid, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA

INDEX

(NAME)


Absolute stereochemistry.



RN 258864-80-1 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxycarbonylphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-81-2 CAPLUS

CN Butanedi-~~am~~ide, N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-82-3 CAPLUS

CN Butanedi-~~am~~ide, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-83-4 CAPLUS

CN Butanedi-~~am~~ide, N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-84-5 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-85-6 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-86-7 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258864-87-8 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258864-88-9 CAPLUS

CN Butanediamide,

3-butyl-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-90-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-91-4 CAPLUS

CN Butanediamic acid, 3-butyl-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-92-5 CAPLUS

CN Butanediamic acid, 3-butyl-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-93-6 CAPLUS

CN Butanediamic acid, 3-butyl-N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-94-7 CAPLUS

CN Butanediamic acid, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-butyl-2-(2-methylpropyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-95-8 CAPLUS

CN Butanedi-2-amine, 3-butyl-1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl)methyl]-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-96-9 CAPLUS

CN Butanedi-2-amine, 2-(cyclopropylmethyl)-1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-97-0 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R, 3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-98-1 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R, 3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258864-99-2 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-00-8 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-01-9 CAPLUS

CN - Butanediamide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-02-0 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-03-1 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


• Absolute stereochemistry.



RN 258865-04-2 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

• Absolute stereochemistry.




RN 258865-05-3 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-

methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-06-4 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-07-5 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-08-6 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-09-7 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-10-0 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-11-1 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-12-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-13-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-14-4 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-15-5 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-16-6 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-17-7 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopropylmethyl)-, (2R,3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-18-8 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-butyl-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-19-9 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-20-2 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-21-3 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-22-4 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-23-5 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-24-6 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-25-7 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-26-8 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-27-9 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-28-0 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258865-29-1 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R, 3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-30-4 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R, 3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-31-5 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-32-6 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-33-7 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-34-8 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-35-9 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R, 3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-36-0 CAPLUS

CN Butanediamide, 3-butyryl-2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-, (2R, 3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-37-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)-

(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-38-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-39-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-40-6 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-41-7 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclobutylmethyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-42-8 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-butyl-2-(cyclobutylmethyl)-, (2R,3S)-(9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 258865-43-9 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-44-0 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-45-1 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-46-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-47-3 CAPLUS .

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-49-5 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-50-8 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-

yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-51-9 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-
azepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 258865-52-0 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-53-1 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[3-(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-54-2 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-55-3 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-56-4 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-57-5 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-58-6 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-59-7 CAPLUS

CN Butanediarnide, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-60-0 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-61-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[3-(phenoxyphenyl)methyl]-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-62-2 CAPLUS

CN Butanedi-2-yl-2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)-

(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-63-3 CAPLUS

CN Butanedi-2-yl-2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-64-4 CAPLUS

CN Butanedi- amide, 3-butyl-2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258865-65-5 CAPLUS

CN Butanedi- amide, 3-butyl-2-(cyclopentylmethyl)-N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-66-6 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(cyclopentylmethyl)-, (2R,3S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-67-7 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-[(3-benzoylphenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-3-butyl-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-68-8 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-69-9 CAPLUS

CN Butanediamide,
N1-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-70-2 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-(2-phenylethyl)-1H-azepin-3-yl]-
2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-71-3 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(4-fluorophenyl)methyl]hexahydro-2-oxo-1H-
azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 258865-72-4 CAPLUS

CN Butanediamide, N1-[(3S)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-

yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-73-5 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-(cyclobutylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-74-6 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-(cyclopentylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-75-7 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-(cyclohexylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-76-8 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-(2-cyclopropylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-77-9 CAPLUS

CN Butanediamide, N1-[(3S)-1-(2-cyclobutylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-78-0 CAPLUS

CN Butanediamide,
N1-[(3S)-1-(2-cyclopentylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-79-1 CAPLUS

CN Butanediamide, N1-[(3S)-1-(2-cyclohexylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-80-4 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-81-5 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-(2-phenylethyl)-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-82-6 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(4-fluorophenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA

INDEX
NAME)


Absolute stereochemistry.



RN 258865-83-7 CAPLUS

CN Butanediamide, N1-[(3S)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-84-8 CAPLUS

CN Butanediamide, N1-[(3S)-1-(cyclobutylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-85-9 CAPLUS

CN Butanediarnide, N1-[(3S)-1-(cyclopentylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-86-0 CAPLUS

CN Butanediarnide, N1-[(3S)-1-(cyclohexylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-87-1 CAPLUS

CN Butanediamide,

N1-[(3S)-1-(2-cyclopropylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-88-2 CAPLUS

CN Butanediamide, N1-[(3S)-1-(2-cyclobutylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-89-3 CAPLUS

CN Butanediamide,

N1-[(3S)-1-(2-cyclopentylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-90-6 CAPLUS

CN Butanediamide, N1-[(3S)-1-(2-cyclohexylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258865-91-7 CAPLUS

CN Butanediamide,

3-butyl-N1-[(3S)-hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-92-8 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-hexahydro-2-oxo-1-(2-phenylethyl)-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-93-9 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-[(4-fluorophenyl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-94-0 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(cyclopropylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-95-1 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[(3S)-1-(cyclobutylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-96-2 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[(3S)-1-(cyclopentylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-97-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(cyclohexylmethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-98-4 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(2-cyclopropylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258865-99-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(2-cyclobutylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-00-1 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(2-cyclopentylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-01-2 CAPLUS

CN Butanediamide, 3-butyl-N1-[(3S)-1-(2-cyclohexylethyl)hexahydro-2-oxo-1H-azepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-02-3 CAPLUS

CN Butanediarnide,
 N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-
 1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-03-4 CAPLUS

CN Butanediarnide,
 N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-
 1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-04-5 CAPLUS

CN Butanediarnide,
 N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-
 2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-,
 (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-05-6 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(tri-fluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-06-7 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-07-8 CAPLUS

CN Butanediarnide, N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-08-9 CAPLUS

CN Butanediarnide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-09-0 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258866-10-3 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-11-4 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-12-5 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-13-6 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-

oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-14-7 CAPLUS

CN Butanediamide, N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-

dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-
propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-15-8 CAPLUS

CN Butanediamide,

N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-

dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-17-0 CAPLUS

CN Butanediamide,

N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-18-1 CAPLUS


CN Butanediamide,

3-butyl-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA

INDEX NAME)


Absolute stereochemistry.



RN 258866-19-2 CAPLUS

CN Butanediamide, 3-butyl-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-20-5 CAPLUS

CN Butanediarnide, 3-butyl-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-21-6 CAPLUS

CN Butanediarnide, 3-butyl-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-22-7 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-

2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-23-8 CAPLUS

CN Butanediamide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME),

Absolute stereochemistry.




RN 258866-24-9 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-butyl-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258866-25-0 CAPLUS

CN Butanediamide, 3-butyl-N1-[2,3-dihydro-1-[[3-(2-

naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-26-1 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-27-2 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl])methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-28-3 CAPLUS

CN Butanediarnide,

2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-29-4 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-


biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-30-7 CAPLUS
 CN Butanediamide,
 2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-31-8 CAPLUS
 CN Butanediamide,
 N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-32-9 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-33-0 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-34-1 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-35-2 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-36-3 CAPLUS -

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-37-4 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-38-5 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-39-6 CAPLUS

CN Butanediamide,

N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-

dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-40-9 CAPLUS

CN Butanediamide,


N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-

1H-1,4-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-,

(2R,3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-41-0 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[[3-(2-

naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-42-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-43-2 CAPLUS


CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-44-3 CAPLUS
 CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-45-4 CAPLUS
 CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-46-5 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-47-6 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-48-7 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-butyl-2-(cyclopropylmethyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-49-8 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-50-1 CAPLUS

Butanediolamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-51-2 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-
 biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-
 , (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-52-3 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-53-4 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-

biphenyl]-3-yl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-


(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-54-5 CAPLUS
 CN Butanediamide,
 2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-55-6 CAPLUS
 CN Butanediamide,
 N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-56-7 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-57-8 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-58-9 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-59-0 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-60-3 CAPLUS

CN Butanedi-2-amine,

2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry:



RN 258866-61-4 CAPLUS

CN Butanedi-2-amine, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-62-5 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-63-6 CAPLUS

CN Butanediamide,


N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- RN 258866-64-7 CAPLUS
 CN Butanediamide,
 N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-
 1H-1,4-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-65-8 CAPLUS
 CN Butanediamide, 2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[[3-(2-
 naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-
 propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-66-9 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-67-0 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-68-1 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclobutylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-

1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-69-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-70-5 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-71-6 CAPLUS

CN Butanediamide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-72-7 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-butyl-2-(cyclobutylmethyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-73-8 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-74-9 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-75-0 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-76-1 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-77-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-

biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-78-3 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-79-4 CAPLUS

CN Butanediamide,

N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-80-7 CAPLUS

CN Butanediarnide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-81-8 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-82-9 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-83-0 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-84-1 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-85-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-86-3 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-87-4 CAPLUS

CN Butanediamide,

N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-88-5 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258866-89-6 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[[3-(2-

naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN • 258866-90-9 .CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-91-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-92-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[2,3-dihydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-92-2 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-94-3 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-95-4 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258866-96-5 CAPLUS


CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-

1H-1,4-benzodiazepin-3-yl]-3-butyl-2-(cyclopentylmethyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258866-97-6 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[2,3-dihydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-98-7 CAPLUS

CN Butanediamic acid, N1-[2,3-dihydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258866-99-8 CAPLUS

CN Butanediamic acid, N1-[2,3-dihydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 258867-00-4P 258867-01-5P 258867-02-6P
258867-03-7P 258867-04-8P 258867-05-9P
258867-06-0P 258867-08-2P 258867-09-3P
258867-10-6P 258867-11-7P 258867-12-8P
258867-13-9P 258867-14-0P 258867-15-1P
258867-16-2P 258867-17-3P 258867-18-4P
258867-19-5P 258867-20-8P 258867-21-9P
258867-22-0P 258867-23-1P 258867-24-2P
258867-25-3P 258867-26-4P 258867-27-5P
258867-28-6P 258867-29-7P 258867-30-0P
258867-31-1P 258867-32-2P 258867-33-3P
258867-34-4P 258867-35-5P 258867-36-6P
258867-37-7P 258867-38-8P 258867-39-9P
258867-40-2P 258867-41-3P 258867-42-4P
258867-43-5P 258867-44-6P 258867-45-7P
258867-47-9P 258867-49-1P 258867-51-5P
258867-53-7P 258867-55-9P 258867-57-1P
258867-59-3P 258867-61-7P 258867-63-9P
258867-64-0P 258867-65-1P 258867-66-2P
258867-67-3P 258867-68-4P 258867-69-5P
258867-70-8P 258867-71-9P 258867-72-0P
258867-73-1P 258867-74-2P 258867-75-3P
258867-76-4P 258867-77-5P 258867-78-6P
258867-79-7P 258867-80-0P 258867-81-1P
258867-82-2P 258867-83-3P 258867-84-4P
258867-85-5P 258867-86-6P 258867-87-7P
258867-88-8P 258867-89-9P 258867-90-2P
258867-91-3P 258867-92-4P 258867-93-5P
258867-94-6P 258867-95-7P 258867-96-8P
258867-97-9P 258867-98-0P 258867-99-1P
258868-00-7P 258868-01-8P 258868-02-9P
258868-03-0P 258868-04-1P 258868-05-2P
258868-06-3P 258868-07-4P 258868-08-5P
258868-09-6P 258868-10-9P 258868-11-0P
258868-12-1P 258868-13-2P 258868-14-3P
258868-15-4P 258868-16-5P 258868-17-6P
258868-18-7P 258868-19-8P 258868-20-1P
258868-21-2P 258868-22-3P 258868-23-4P
258868-24-5P 258868-25-6P 258868-26-7P
258868-27-8P 258868-28-9P 258868-29-0P
258868-30-3P 258868-32-5P 258868-34-7P
258868-36-9P 258868-38-1P 258868-40-5P
258868-42-7P 258868-43-8P 258868-44-9P
258868-46-1P 258868-47-2P 258868-49-4P
258868-50-7P 258868-51-8P 258868-52-9P
258868-53-0P 258868-54-1P 258868-55-2P
258868-56-3P 258868-57-4P 258868-58-5P
258868-59-6P 258868-60-9P 258868-61-0P
258868-62-1P 258868-63-2P 258868-64-3P
258868-65-4P 258868-66-5P 258868-67-6P
258868-68-7P 258868-69-8P 258868-70-1P
258868-71-2P 258868-72-3P 258868-73-4P
258868-74-5P 258868-75-6P 258868-76-7P
258868-77-8P 258868-78-9P 258868-79-0P
258868-80-3P 258868-81-4P 258868-82-5P
258868-83-6P 258868-84-7P 258868-85-8P
258868-86-9P 258868-87-0P 258868-88-1P
258868-89-2P 258868-90-5P 258868-91-6P
258868-92-7P 258868-93-8P 258868-95-0P

258868-97-2P 258868-99-4P 258869-01-1P
 258869-03-3P 258869-04-4P 258869-06-6P
 258869-07-7P 258869-08-8P 258869-09-9P
 258869-10-2P 258869-11-3P 258869-12-4P
 258869-13-5P 258869-14-6P 258869-15-7P
 258869-16-8P 258869-17-9P 258869-18-0P
 258869-19-1P 258869-20-4P 258869-21-5P
 258869-22-6P 258869-23-7P 258869-24-8P
 258869-25-9P 258869-26-0P 258869-27-1P
 258869-28-2P 258869-29-3P 258869-30-6P
 258869-31-7P 258869-32-8P 258869-33-9P
 258869-34-0P 258869-35-1P 258869-36-2P
 258869-37-3P 258869-38-4P 258869-39-5P
 258869-40-8P 258869-41-9P 258869-42-0P
 258869-43-1P 258869-44-2P 258869-45-3P
 258869-46-4P 258869-47-5P 258869-48-6P
 258869-49-7P 258869-50-0P 258869-51-1P
 258869-52-2P 258869-53-3P 258869-54-4P
 258869-55-5P 258869-56-6P 258869-57-7P
 258869-58-8P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of succinoylaminoazepinones and related compds. as inhibitors of A.beta.-peptide prodn.)

RN 258867-00-4 CAPLUS

CN Butanediamide, N1-[1-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-01-5 CAPLUS

CN Butanediamide,
 N1-[1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-02-6 CAPLUS

CN Butanediamide,

N1-[1-(cyclobutylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-03-7 CAPLUS

CN Butanediamide,

N1-[1-(cyclopentylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-04-8 CAPLUS

CN Butanediamide,

N1-[1-(cyclohexylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-05-9 CAPLUS

CN Butanediamide, N1-[1-(2-cyclopropylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-06-0 CAPLUS

CN Butanedi-2,3-diamide,

N1-[1-(2-cyclobutylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-08-2 CAPLUS

CN Butanedi-2,3-diamide, N1-[1-(2-cyclopentylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-09-3 CAPLUS

CN Butanedi-2,3-diamide,

N1-[1-(2-cyclohexylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-10-6 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-11-7 CAPLUS

CN Butanediamide, N1-[2,3-dihydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-12-8 CAPLUS

CN Butanediamide, N1-[1-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-13-9 CAPLUS

CN Butanedi-2-amine,

N1-[1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-14-0 CAPLUS

CN Butanedi-2-amine,

N1-[1-(cyclobutylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-15-1 CAPLUS

CN Butanediamide,

N1-[1-(cyclopentylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-16-2 CAPLUS

CN Butanediamide,

N1-[1-(cyclohexylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-17-3 CAPLUS

CN Butanedi-2-amine, N1-[1-(2-cyclopropylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-18-4 CAPLUS

CN Butanedi-2-amine, N1-[1-(2-cyclobutylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-19-5 CAPLUS

CN Butanediamide, N1-[1-(2-cyclopentylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-20-8 CAPLUS

CN Butanediamide,
N1-[1-(2-cyclohexylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-21-9 CAPLUS

CN Butanediamide,
3-butyl-N1-[2,3-dihydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-22-0 CAPLUS

CN Butanediamide,

3-butyl-N1-[2,3-dihydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-23-1 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-[(4-fluorophenyl)methyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-24-2 CAPLUS

CN Butanediamide, 3-butyl-N1-[1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-25-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[1-(cyclobutylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-26-4 CAPLUS

CN Butanediarnide, 3-butyl-N1-[1-(cyclopentylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-27-5 CAPLUS

CN Butanediarnide, 3-butyl-N1-[1-(cyclohexylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-28-6 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[1-(2-cyclopropylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-29-7 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[1-(2-cyclobutylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.




RN. 258867-30-0 CAPLUS
 CN Butanedi-2-amine, 3-butyl-N1-[1-(2-cyclopentylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-31-1 CAPLUS
 CN Butanedi-2-amine, 3-butyl-N1-[1-(2-cyclohexylethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 258867-32-2 CAPLUS
 CN Butanedi-2-amine, N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-33-3 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-34-4 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-35-5 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-36-6 CAPLUS

CN Butanediamide, N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-37-7 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-38-8 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-39-9 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-40-2 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258867-41-3 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-
6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-42-4 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-

biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-
propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-43-5 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-44-6 CAPLUS

CN Butanediamide, N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-45-7 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-

dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-
, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-47-9 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-
5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-49-1 CAPLUS

CN Butanediarnide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-51-5 CAPLUS

CN Butanediarnide, 3-butyl-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-53-7 CAPLUS

CN Butanediamide,

3-butyl-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-55-9 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-57-1 CAPLUS

CN Butanediamide,

3-butyl-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-
6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-,
(2R,3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-59-3 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-

yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-61-7 CAPLUS

CN Butanedi-2,3-diamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-63-9 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-64-0 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-65-1 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-66-2 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-67-3 CAPLUS

CN Butanediarnide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-68-4 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-69-5 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-70-8 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-71-9 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-72-0 CAPLUS

CN Butanedi-2,3-diamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-73-1 CAPLUS

CN Butanedi-2,3-diamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-74-2 CAPLUS

¹CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-75-3 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-76-4 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-

3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-77-5 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-

dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-(2-
propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-78-6 CAPLUS

CN Butanedi-2-amine, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-79-7 CAPLUS

CN Butanedi-2-amine, 2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-80-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-81-1 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-82-2 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-

(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-83-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-84-4 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-85-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-86-6 CAPLUS

CN Butanedi-2-amine, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclopropylmethyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-87-7 CAPLUS

CN Butanedi-2-amine, 3-butyl-2-(cyclopropylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-88-8 CAPLUS

CN Butanedi-2-amine, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-89-9 CAPLUS

CN Butanedi-2-amine, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-90-2 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-91-3 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-92-4 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258867-93-5 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-propyl-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-94-6 CAPLUS

CN Butanediarnide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258867-95-7 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-96-8 CAPLUS

CN Butanedi-2-amine, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-97-9 CAPLUS

CN Butanedi-2-amine, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-98-0 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258867-99-1 CAPLUS

CN Butanediamide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[4'-(4-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-00-7 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-

3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-01-8 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-
dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-(2-
propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-02-9 CAPLUS

CN Butanediarnide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


• Absolute stereochemistry.



RN 258868-03-0 CAPLUS

CN Butanediarnide, 2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-04-1 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-05-2 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-06-3 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-07-4 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-08-5 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-2-(cyclobutylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-09-6 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclobutylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-10-9 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclobutylmethyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258868-11-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclobutylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-12-1 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 258868-13-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-14-3 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-15-4 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-16-5 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-17-6 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-18-7 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-19-8 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-20-1 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-21-2 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-22-3 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-23-4 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-24-5 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-25-6 CAPLUS

CN Butanediamide,

N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-26-7 CAPLUS

CN Butanediamide, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-27-8 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-28-9 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[(3-phenoxyphenyl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-29-0 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-30-3 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-6-oxo-5-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-32-5 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-34-7 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopentylmethyl)-N1-[5-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-36-9 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[5-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-38-1 CAPLUS

CN Butanedi-2-amine, N1-[5-[(3-benzoylphenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-3-butyl-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-40-5 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-2-(cyclopentylmethyl)-N1-[6,7-dihydro-5-[[3-(2-naphthalenyl)phenyl]methyl]-6-oxo-5H-dibenz[b,d]azepin-7-yl]-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-42-7 CAPLUS

CN Butanedi-2,3-diamide, N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-43-8 CAPLUS

CN Butanediame, N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 258868-44-9 CAPLUS

CN Butanediame, N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 258868-46-1 CAPLUS

CN Butanediamide, N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI), (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-47-2 CAPLUS


CN Butanediamide, N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-49-4 CAPLUS
 CN Butanediamide, N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258868-50-7 CAPLUS
 CN Butanediamide, N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-51-8 CAPLUS

CN Butanediamide, N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-52-9 CAPLUS

CN Butanediamide, N1-[5-(2-cyclobutylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-53-0 CAPLUS

CN Butanediamide, N1-[5-(2-cyclopentylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-54-1 CAPLUS

CN Butanediamide, N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-55-2 CAPLUS

CN Butanediamide,

N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-56-3 CAPLUS

CN Butanediamide, N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-57-4 CAPLUS

CN Butanediarnide, N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-58-5 CAPLUS

CN Butanediarnide, N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-59-6 CAPLUS

CN Butanediamide, N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-60-9 CAPLUS

CN Butanediamide, N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-61-0 CAPLUS

CN Butanediamide, N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258868-62-1 CAPLUS


CN Butanediamide, N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



RN 258868-65-4 CAPLUS

CN Butanediamide, N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
 (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-66-5 CAPLUS

CN Butanediamide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-(phenylmethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-67-6 CAPLUS

CN Butanediarnide, 3-butyl-N1-[6,7-dihydro-6-oxo-5-(2-phenylethyl)-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-68-7 CAPLUS

CN Butanediarnide, 3-butyl-N1-[5-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-69-8 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[5-(cyclopropylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-70-1 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[5-(cyclobutylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-71-2 CAPLUS

CN Butanediameide, 3-butyl-N1-[5-(cyclopentylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-72-3 CAPLUS

CN Butanediameide, 3-butyl-N1-[5-(cyclohexylmethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-73-4 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[5-(2-cyclopropylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-74-5 CAPLUS

CN Butanedi-2,3-diamide, 3-butyl-N1-[5-(2-cyclobutylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-75-6 CAPLUS

CN Butanediarnide, 3-butyl-N1-[5-(2-cyclopentylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-76-7 CAPLUS

CN Butanediarnide, 3-butyl-N1-[5-(2-cyclohexylethyl)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-77-8 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-1-
[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-78-9 CAPLUS

CN Butanediamide, 2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-
methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-
yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-79-0 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-80-3 CAPLUS

CN Butanediamide, 2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-81-4 CAPLUS

CN Butanediamide,

N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-

tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-82-5 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-83-6 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-84-7 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[[3-(2-naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-85-8 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-86-9 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-87-0 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-88-1 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[[4'-methyl[1,1'-biphenyl]-3-yl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-89-2 CAPLUS

CN Butanediamide,

N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-

tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-90-5 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258868-91-6 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-
[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-
yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-92-7 CAPLUS

CN Butanediamide, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-2-oxo-1-
[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-93-8 CAPLUS

CN Butanediamide, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-95-0 CAPLUS

CN Butanediamide, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-97-2 CAPLUS

CN Butanediamide, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258868-99-4 CAPLUS

CN Butanediamide, 3-butyl-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-01-1 CAPLUS

CN Butanediarnide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-03-3 CAPLUS

CN Butanediarnide,
N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-butyl-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-04-4 CAPLUS

CN Butanediamide,

3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-06-6 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-07-7 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[[4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-08-8 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-09-9 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-10-2 CAPLUS

CN Butanediamide, 2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-11-3 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-12-4 CAPLUS

CN Butanediamide,
N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-13-5 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[[3-

(2'-naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-14-6 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-15-7 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-16-8 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-17-9 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-18-0 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-19-1 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-20-4 CAPLUS

CN Butanediamide, N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-21-5 CAPLUS

CN Butanediamide,

2-(cyclopropylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258869-22-6 CAPLUS

CN Butanediamide,


3-butyl-2-(cyclopropylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-

1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,

(2R,3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-23-7 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopropylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-

méthoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-24-8 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopropylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-25-9 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopropylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-26-0 CAPLUS

CN Butanediamide, 3-butyl-2-(cyclopropylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-27-1 CAPLUS

CN Butanediarnide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-28-2 CAPLUS

CN Butanediarnide,
N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-butyl-2-(cyclopropylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-29-3 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopropylmethyl)-N1-[2,3,4,5-tetrahydro-1-[[3-

(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R, 3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-30-6 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-
1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R, 3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-31-7 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-

methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-32-8 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-

5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-33-9 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-34-0 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-35-1 CAPLUS

CN Butanedi- amide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-36-2 CAPLUS

CN Butanedi- amide, N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-37-3 CAPLUS

CN Butanediarnide,

2-(cyclobutylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(3-

(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-38-4 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-39-5 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-40-8 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-41-9 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-42-0 CAPLUS

CN Butanediamide,

2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-43-1 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-44-2 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-45-3 CAPLUS

CN Butanediarnide,

2-(cyclobutylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

1-[[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-46-4 CAPLUS

CN Butanediarnide,

3-butyl-2-(cyclobutylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-1-

[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-47-5 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclobutylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-

methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-48-6 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclobutylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-

p-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-49-7 CAPLUS

CN Butanediarnide,

3-butyl-2-(cyclobutylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-50-0 CAPLUS

CN Butanediarnide, 3-butyl-2-(cyclobutylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-51-1 CAPLUS

CN Butanediarnide, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclobutylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-52-2 CAPLUS

CN Butanediarnide, N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-butyl-2-(cyclobutylmethyl)-, (2R,3S)- (9GI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-53-3 CAPLUS

CN Butanedi-2-amine, 3-butyl-2-(cyclobutylmethyl)-N1-[2,3,4,5-tetrahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-54-4 CAPLUS

CN Butanedi-2-amine, 2-(cyclopentylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-1-[(3-phenoxycyclohexyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-55-5 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-56-6 CAPLUS

CN Butanediarnide, 2-(cyclopentylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-57-7 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-58-8 CAPLUS

CN Butanediamide, 2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 258869-59-9P 258869-60-2P 258869-61-3P
 258869-62-4P 258869-63-5P 258869-64-6P
 258869-65-7P 258869-66-8P 258869-67-9P
 258869-68-0P 258869-69-1P 258869-70-4P
 258869-71-5P 258869-72-6P 258869-73-7P
 258869-74-8P 258869-75-9P 258869-76-0P
 258869-77-1P 258869-78-2P 258869-79-3P
 258869-80-6P 258869-81-7P 258869-82-8P
 258869-83-9P 258869-84-0P 258869-85-1P
 258869-86-2P 258869-87-3P 258869-88-4P
 258869-89-5P 258869-90-8P 258869-91-9P
 258869-92-0P 258869-93-1P 258869-94-2P
 258869-95-3P 258869-96-4P 258869-97-5P
 258869-98-6P 258869-99-7P 258870-00-7P
 258870-01-8P 258870-02-9P 258870-03-0P
 258870-04-1P 258870-05-2P 258870-06-3P
 258870-07-4P 258870-08-5P 258870-10-9P
 258870-11-0P 258870-12-1P 258870-13-2P
 258870-14-3P 258870-15-4P 258870-16-5P
 258870-17-6P 258870-18-7P 258870-19-8P
 258870-20-1P 258870-21-2P 258870-22-3P
 258870-23-4P 258870-24-5P 258870-25-6P
 258870-26-7P 258870-27-8P 258870-28-9P
 258870-29-0P 258870-30-3P 258870-31-4P
 258870-32-5P 258870-33-6P 258870-34-7P
 258870-65-4P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of succinoylaminoazepinones and related compds. as inhibitors of A.beta.-peptide prodn.)

RN 258869-59-9 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-60-2 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-61-3 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-propyl-N1-[2,3,4,5-tetrahydro-1-[(3-(2-naphthalenyl)phenyl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-62-4 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-
2-oxo-1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-63-5 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-
1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-
benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-64-6 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-65-7 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-

1-[[4'-methyl[1,1'-biphenyl]-3-yl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-66-8 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-

3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-67-9 CAPLUS

CN Butanediamide, N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-68-0 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-3-(2-propenyl)-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-69-1 CAPLUS

CN Butanediamide,

2-(cyclopentylmethyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-


1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-70-4 CAPLUS
 CN Butanediamide,
 3-butyl-2-(cyclopentylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-
 1-[(3-phenoxyphenyl)methyl]-5-phenyl-1H-1,5-benzodiazepin-3-yl]-,
 (2R,3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258869-71-5 CAPLUS
 CN Butanediamide,
 3-butyl-2-(cyclopentylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-
 methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-
 yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-72-6 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopentylmethyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-73-7 CAPLUS

CN Butanediamide,

3-butyl-2-(cyclopentylmethyl)-N1-[2,3,4,5-tetrahydro-1-[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-74-8 CAPLUS

CN Butanedi-2-amine, 3-butyl-2-(cyclopentylmethyl)-N1-[1-[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-75-9 CAPLUS

CN Butanedi-2-amine, 3-butyl-N1-[1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(cyclopentylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-76-0 CAPLUS

CN Butanediamide,

N1-[1-[(3-benzoylphenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-3-butyl-2-(cyclopentylmethyl)-, (2R,3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-77-1 CAPLUS

CN Butanediamide,


3-butyl-2-(cyclopentylmethyl)-N1-[2,3,4,5-tetrahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-78-2 CAPLUS
 CN Butanediamide,
 2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258869-79-3 CAPLUS
 CN Butanediamide,
 2-(2-methylpropyl)-3-propyl-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-80-6 CAPLUS

CN Butanedi-2,3-diamide, N1-[1-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-81-7 CAPLUS

CN Butanedi-2,3-diamide, N1-[1-(cyclopropylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-82-8 CAPLUS

CN Butanediamide,

N1-[1-(cyclobutylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258869-83-9 CAPLUS

CN Butanediamide,

N1-[1-(cyclopentylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258869-84-0 CAPLUS

CN Butanediamide,

N1-[1-(cyclohexylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258869-85-1 CAPLUS

CN Butanediamide, N1-[1-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-86-2 CAPLUS

CN Butanedi-2,3-diamide,

N1-[1-(2-cyclobutylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 258869-87-3 CAPLUS

CN Butanedi-2,3-diamide, N1-[1-(2-cyclopentylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-88-4 CAPLUS

CN Butanedi-2,3-diamide,

N1-[1-(2-cyclohexylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258869-89-5 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258869-90-8 CAPLUS

CN Butanediamide,

2-(2-methylpropyl)-3-(2-propenyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258869-91-9 CAPLUS

CN Butanediamide, N1-[1-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-

phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-,
(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-92-0 CAPLUS

CN Butanediamide,

N1-[1-(cyclopropylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-
1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-93-1 CAPLUS

CN Butanediamide,

N1-[1-(cyclobutylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-
1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-94-2 CAPLUS

CN Butanediamide,

N1-[1-(cyclopentylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

• Absolute stereochemistry.




RN 258869-95-3 CAPLUS

CN Butanediamide,

N1-[1-(cyclohexylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-96-4 CAPLUS

CN Butanedi-2-amine, N1-[1-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-97-5 CAPLUS

CN Butanedi-2-amine, N1-[1-(2-cyclobutylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258869-98-6 CAPLUS

CN Butanedi-*amide*, N1-[1-(2-cyclopentylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258869-99-7 CAPLUS

CN Butanedi-*amide*,

N1-[1-(2-cyclohexylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-00-7 CAPLUS


CN Butanedi-*amide*, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(phenylmethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-01-8 CAPLUS
 CN Butanediamide, 3-butyl-2-(2-methylpropyl)-N1-[2,3,4,5-tetrahydro-2-oxo-5-phenyl-1-(2-phenylethyl)-1H-1,5-benzodiazepin-3-yl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-02-9 CAPLUS
 CN Butanediamide,
 3-butyl-N1-[1-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258870-03-0 CAPLUS
 CN Butanediamide,
 3-butyl-N1-[1-(cyclopropylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258870-04-1 CAPLUS


CN Butanediarnide,

3-butyl-N1-[1-(cyclobutylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.




RN 258870-05-2 CAPLUS

CN Butanediarnide,

3-butyl-N1-[1-(cyclopentylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-06-3 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-(cyclohexylmethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-07-4 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-oxo-5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-08-5 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-(2-cyclobutylethyl)-2,3,4,5-tetrahydro-2-oxo-
5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-10-9 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-(2-cyclopentylethyl)-2,3,4,5-tetrahydro-2-oxo-
5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-11-0 CAPLUS

CN Butanediamide,

3-butyl-N1-[1-(2-cyclohexylethyl)-2,3,4,5-tetrahydro-2-oxo-
5-phenyl-1H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-12-1 CAPLUS

CN Butanediamide,

N1-[(3S)-1-(3,3-diphenylpropyl)hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-13-2 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-14-3 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-phenyl-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-15-4 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-methyl-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-16-5 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-methoxy-N4-methyl-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-17-6 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-methoxy-N4-methyl-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-18-7 CAPLUS

CN Hexanoic acid, 3-[[[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]amino]carbonyl]-5-methyl-2-propyl-, hydrazide, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-19-8 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-(2-propenyl)-, (2R,3S)- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 258870-20-1 CAPLUS

CN Butanedi-2-amine, N1-[(3S)-1-[(2',4'-dichloro[1,1'-biphenyl]-3-

yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-21-2 CAPLUS

CN Butanediamide,

N1-[(3S)-1-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-
2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-22-3 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(4'-methyl[1,1'-biphenyl]-3-
yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-,
(2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-23-4 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[(4'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-24-5 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[(3'-methyl[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-25-6 CAPLUS

CN Butanediamic acid, N1-[(3S)-1-[(3'-chloro-4'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-26-7 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)methyl]-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-27-8 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-1-[(3'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-28-9 CAPLUS

CN Butanediamide, N1-[(3S)-1-[(3'-fluoro[1,1'-biphenyl]-3-yl)methyl]hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-29-0 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[(2'-methoxy[1,1'-biphenyl]-3-yl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-30-3 CAPLUS

CN Butanediamic acid, N1-[(3S)-hexahydro-1-[[3-(2-naphthalenyl)phenyl]methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-31-4 CAPLUS

CN Butanediarnide, N4-butyl-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 258870-32-5 CAPLUS

CN Butanediarnide, N4-(2-furanylmethyl)-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-33-6 CAPLUS

CN Butanediarnide, N4-cyclopentyl-N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)-(9CI) (CA INDEX NAME)

(2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 258870-34-7 CAPLUS

CN Butanediarnide, N1-[(3S)-hexahydro-2-oxo-1-[(3-phenoxyphenyl)methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-N4-(3-phenyl-2-propenyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 258870-65-4 CAPLUS

CN Butanediarnide, N1-[(3S)-hexahydro-2-oxo-1-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-azepin-3-yl]-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **258870-70-1D**, resin-bound

RL: RCT (Reactant)


(prepn. of succinoylaminoazepinones and related compds. as inhibitors of A.beta.-peptide prodn.)

RN 258870-70-1 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-1-[(3-iodophenyl)methyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5

RE

- (1) Eli Lilly And Company; EP 0652009 A 1995 CAPLUS
- (2) Natchus, M; BIOORG MED CHEM LETT 1998, V8(16), P2077 CAPLUS
- (3) Otsuka Pharmaceutical Co Ltd; US 5594006 A 1997 CAPLUS
- (4) Pharmacopeia Inc; US 5734054 A 1998 CAPLUS
- (5) The Procter & Gamble Company; WO 9629313 A 1996 CAPLUS

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1998:754590 CAPLUS

DN 130:168629

TI Active conformation and peptidase resistance of conformationally restricted analogs of the insect allatostatin neuropeptide family

AU Nachman, R. J.; Moyna, G.; Williams, H. J.; Garside, C.; Tobe, S. S.

CS Veterinary Entomology Research Unit, FAPRL, U.S. Department of Agriculture, College Station, TX, USA

SO Adv. Comp. Endocrinol., Proc. Int. Congr. Comp. Endocrinol., 13th (1997), Volume 2, 1353-1359. Editor(s): Kawashima, Seiichiro; Kikuyama, Sakae. Publisher: Monduzzi Editore, Bologna, Italy. CODEN: 66ZWA3

DT Conference

LA English

AB The authors address through the design, synthesis and biol. evaluation of a series of linear mimetic allatostatin analogs contg. conformationally restricted components within the C-terminal pentapeptide active core sequence. As these conformationally restricted analogs necessarily involve incorporation of sterically hindered mol. structures, these analogs have been addnl. tested for patterns of hydrolysis via hemolymph and tissue-bound peptidases.


IT **220382-58-1P**
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (allatostatin conformationally restricted analogs and their resistance to peptidase)

RN 220382-58-1 CAPLUS


CN L-Leucinamide,
 L-alanyl-L-arginyl-L-prolyl-L-tyrosyl-L-asparaginyl-3-amino-
 2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetyl- (9CI) (CA INDEX NAME)

- Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 4

RE

- (1) Bendena, W; Annals NY Acad Sci 1997, V814, P53 CAPLUS
- (2) Hayes, T; Peptides 1994, V15, P1165 CAPLUS
- (3) James, G; Science 1993, V260, P1937 CAPLUS
- (4) Toniolo, C; Biopolymers 1983, V22, P205 CAPLUS

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1998:617888 CAPLUS

DN 129:302872

TI Synthesis, biological activity, and conformational studies of insect allatostatin neuropeptide analogs incorporating turn-promoting moieties

AU Nachman, Ronald J.; Moyna, Guillermo; Williams, Howard J.; Tobe, Stephen S.; Scott, A. I.

CS Veterinary Entomology Research Unit, FAPRL, Agricultural Research Service,

USDA, College Station, TX, 77845-2122, USA

SO Bioorg. Med. Chem. (1998), 6(8), 1379-1388

CODEN: BMECEP; ISSN: 0968-0896

PB Elsevier Science Ltd.

DT Journal

LA English

AB Allatostatins are 6-18 residue peptides synthesized by insects to control prodn. of juvenile hormones, which in turn regulate functions including metamorphosis and egg prodn. Four insect allatostatin neuropeptide analogs incorporating turn-promoting pseudopeptide moieties in the region responsible for biol. activity were prepd. by solid phase peptide synthetic methods. Bioassay indicated that activities approached those

of

the natural neuropeptides, and mol. models based on NMR data showed similar conformations and the presence of a .beta.-turn in the active

core

region for the four analogs. Differences in activity are believed to be due to differences in bulk and relative position of atoms in the

unnatural

portion of the analogs, and their differing degrees of conformational freedom. The studies support the feasibility of development of neuropeptide-based insect control agents resistant to peptidase

deactivation.

IT 214470-31-2P 214470-32-3P

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn., biol. activity, and conformational studies of insect allatostatin neuropeptide analogs incorporating .beta.-turn-promoting moieties)


RN 214470-31-2 CAPLUS

CN L-Leucinamide,


L-alanyl-L-arginyl-L-prolyl-L-tyrosyl-L-asparaginyl-(3S)-3-amino-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 214470-32-3 CAPLUS

CN L-Leucinamide,


L-alanyl-L-arginyl-L-prolyl-L-tyrosyl-L-asparaginyl-(3R)-3-
 amino-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-1-acetyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1998:606870 CAPLUS

DN 129:290051

TI Design and synthesis of conformationally constrained MMP inhibitors

AU Natchus, Michael G.; Cheng, Menyan; Wahl, Christopher T.; Pikul, Stanislaw; Almstead, Neil G.; Bradley, Rimma S.; Taiwo, Yetunde O.; Mieling, Glen E.; Dunaway, C. Michelle; Snider, Catherine E.; McIver, John M.; Barnett, Bobby L.; McPhail, Sara J.; Anastasio, Melanie B.; De, Biswanath
 CS Procter and Gamble Pharmaceuticals, Health Care Research Center, Mason, OH, 45040, USA
 SO Bioorg. Med. Chem. Lett. (1998), 8(16), 2077-2080
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI



AB A novel series of conformationally constrained matrix metalloprotease inhibitors, e.g., I, was identified. The potencies obsd. for these inhibitors were highly dependent upon the substitution pattern on the caprolactam ring as well as the succinate moiety.


IT 183665-06-7P 183665-17-0P 183665-18-1P
 183665-20-5P 183665-22-7P 183665-23-8P
 183665-29-4P 183665-33-0P 183901-50-0P
 214134-03-9P 214134-05-1P 214134-06-2P
 214134-08-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (conformationally constrained MMP inhibitors)

RN 183665-06-7 CAPLUS


CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-oxo-, methyl ester, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-17-0 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-1-oxoheptyl]amino]-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183665-18-1 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-20-5 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-
N4-hydroxy-2-octyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-22-7 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-oxo-, methyl ester,
(3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183665-23-8 CAPLUS


CN 1H-Azepine-1-acetic acid,

hexahydro-3-[[[(2R,3S)-3-[(hydroxyamino)carbonyl]-

2-(2-methylpropyl)-1-oxohexyl]amino]-2-oxo-, methyl ester, (3S)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 183665-29-4 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[[(2R)-2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, (3S)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 183665-33-0 CAPLUS

CN Butanediamide,

N4-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-

N1-hydroxy-2-methyl-3-octyl-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183901-50-0 CAPLUS

CN Butanediamide,

N4-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-

N1-hydroxy-2-methyl-3-octyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 214134-03-9 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-2-oxo-1-(2-phenoxyethyl)-1H-azepin-3-yl]-
N4-hydroxy-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 214134-05-1 CAPLUS

CN Butanediamide, N1-[(3S)-hexahydro-2-oxo-1-(3-phenoxypropyl)-1H-azepin-3-yl]-
N4-hydroxy-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 214134-06-2 CAPLUS

CN Butanediamide,


N1-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-
N4-hydroxy-2-(2-methylpropyl)-3-propyl-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 214134-08-4 CAPLUS
 CN Butanediamide,
 N4-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-
 N1-hydroxy-2-(3-hydroxypropyl)-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



IT 183665-96-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (conformationally constrained MMP inhibitors)
 RN 183665-96-5 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[[(2R,3S)-2-(2-methylpropyl)-1-oxo-3-
 .[(phenylmethoxy)amino]carbonyl]-5-hexenyl]amino]-2-oxo-, methyl ester,
 (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:268485 CAPLUS
 DN 128:321931
 TI Preparation of heteroaryl succinamides as metalloproteinase inhibitors
 IN Bender, Steven L.; Castelhana, Arlindo L.; Chong, Wesley K. M.; Abreo,
 Melwyn A.; Billedeau, Roland J.; Chen, Jian Jeffrey; Deal, Judith G.
 PA Agouron Pharmaceuticals, Inc., USA; Syntex (U.S.A.) Inc.
 SO PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9817643	A1	19980430	WO 1997-US17809	19971006
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6008243	A	19991228	US 1997-823962	19970325
	AU 9748060	A1	19980515	AU 1997-48060	19971006
	EP 937042	A1	19990825	EP 1997-910770	19971006
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	CN 1233237	A	19991027	CN 1997-198705	19971006
	BR 9713278	A	19991103	BR 1997-13278	19971006
	JP 2000511201	T2	20000829	JP 1998-519394	19971006
	ZA 9709406	A	19980709	ZA 1997-9406	19971021
	NO 9901922	A	19990422	NO 1999-1922	19990422
PRAI	US 1996-29115		19961024		
	US 1997-823962		19970325		
	WO 1997-US17809		19971006		
OS	MARPAT 128:321931				
GI					



AB The present invention is directed to title compds. I [X = bond, (un)branched, (un)satd. C1-6 alkyl optionally contg. O or S atoms, and optionally substituted by F; Y = bond, CH(OH), CO; R1 = H, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl; R2 = any group R1, COR10; R3 = any group R1, NR11R12, OR11; or R2R3 form cycloalkyl or heterocycloalkyl group; R4 = H, suitable org. moiety; R5 = CONHOH, CO2R13, SH, N(OH)CHO, SCOR14, P(O)(OH)R15, P(O)(OH)OR13; R11 = any group R1, alkoxy; R12 = any group R1; NR12R12 = heteroaryl, heterocycloalkyl; R13 = H, alkyl, aryl; R14 = alkyl, aryl; R15 = alkyl; Q = 5-membered heteroaryl ring contg. 1-3 heteroatoms O, S, N] and pharmaceutically acceptable salts and solvates thereof, and pharmaceutically acceptable prodrugs thereof. Compds. I are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amt. of the inventive compds.


Thus, cyclocondensation of Boc-D-Asp(OCH₂Ph)-L-Pheol (Boc = Me₃CO₂C; Pheol = phenylalaninol) (prepn. given) with 3-(4-biphenyl)2,5-dimethoxytetrahydrofuran (prepn. given) and catalytic hydrogenolysis gave pyrrole analog II. II and .apprx.60 related heterocycles were tested for inhibitory activity against a variety of metalloproteinases.

IT **207118-81-8P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of heteroaryl succinamides as metalloproteinase inhibitors)

RN 207118-81-8 CAPLUS

CN Butanediamide, 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-1-yl)-N1-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **207119-55-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of heteroaryl succinamides as metalloproteinase inhibitors)

RN 207119-55-9 CAPLUS


CN Butanediamide, 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-1-yl)-N1-[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]-N4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1997:278955 CAPLUS
 DN 126:264355
 TI Preparation of N-containing compounds as Fas ligand solubilization inhibitors
 IN Hirano, Takao; Yagita, Hideo; Okumura, Ko; Hirayama, Ryoichi; Yamamoto, Minoru; Ebata, Tomohiko; Ohmoto, Hiroshi; Ikeda, Shoji; Yoshino, Kohichiro
 PA Kanebo, Ltd., Japan; Hirano, Takao; Yagita, Hideo; Okumura, Ko; Hirayama, Ryoichi; Yamamoto, Minoru; Ebata, Tomohiko; Ohmoto, Hiroshi; Ikeda, Shoji; Yoshino, Kohichiro
 SO PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709066	A1	19970313	WO 1996-JP2492	19960904
	W: CA, CN, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	EP 848957	A1	19980624	EP 1996-929510	19960904
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	JP 09188631	A2	19970722	JP 1996-257868	19960906
PRAI	JP 1995-256897		19950908		
	JP 1995-317136		19951109		
	WO 1996-JP2492		19960904		
OS	MARPAT 126:264355				
GI					



AB The title compds. (I; A = N-hydroxyaminocarbonyl, CO₂H, SH, etc.; R₁ = H, NH₂, OH, SH, C1-6 alkoxy or alkyl, etc.; R₂ = H, C1-6 alkyl or alkylthio, C2-6 alkenyl, etc.; R₃ = C1-6 alkyl, C2-6 alkenyl, etc.; R₄ = H, C1-6 alkyl or alkoxy, etc.; R₅ = H, C1-6 alkyl, etc.; R₆ = H, OH, C1-6 alkoxy, etc.; R₇ = H, OH, OMe; n = 5-7) or pharmaceutically acceptable salts thereof are prepd. I, having a matrix metalloprotease inhibitory activity, are useful as Fas ligand solubilization inhibitors in the prevention or treatment of diseases caused by solubilized Fas ligands

such

as hepatitis, GVHD, AIDS, and autoimmune diseases. Thus, L-alanine deriv.

(II) was hydrogenated over Pd/C, reacted with C₆H₄CH₂ONH₂.HCl in the presence of WSC, Et₃N, and hydroxybenzotriazole, and then hydrogenated again over Pd/C to give the title compd. (III). III showed 50% Fas ligand

secretion inhibitory when tested on mouse p.o.

IT 188728-51-0P 188728-52-1P 188728-53-2P
188728-54-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-contg. compds. as Fas ligand solubilization inhibitors)

RN 188728-51-0 CAPLUS

CN Butanediamide, N4-hydroxy-2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188728-52-1 CAPLUS

CN Butanediamide,

2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N1-hydroxy-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(3S*)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188728-53-2 CAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(3S*)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188728-54-3 CAPLUS

GN Butanediamide, N4-hydroxy-2-(2-methylpropyl)-3-[(phenylthio)methyl]-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 188728-91-8P 188728-93-0P 188728-95-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N-contg. compds. as Fas ligand solubilization inhibitors)

RN 188728-91-8 CAPLUS

CN Butanediamide, 2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*)]]-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188728-93-0 CAPLUS

CN Butanediamide, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(3S*)]]-[partial]- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 188728-95-2 CAPLUS

CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(3S*)]]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2001 ACS


AN 1996:731972 CAPLUS

DN 126:8011

TI Preparation of 3-[(hydroxaminocarbonyl)alkanamido]caprolactams and analogs

as matrix metalloprotease inhibitors
 IN De, Biswanath; Cheng, Menyen; Natchus, Michael George; Wahl, Christopher Thomas
 PA Procter and Gamble Company, USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9629313	A1	19960926	WO 1996-US3726	19960319
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	US 5672598	A	19970930	US 1995-407839	19950321
	CA 2216129	AA	19960926	CA 1996-2216129	19960319
	AU 9652558	A1	19961008	AU 1996-52558	19960319
	AU 711889	B2	19991021		
	EP 815084	A1	19980107	EP 1996-908856	19960319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI	CN 1179151	A	19980415	CN 1996-192669	19960319
	BR 9607772	A	19980707	BR 1996-7772	19960319
	JP 11502523	T2	19990302	JP 1996-528560	19960319
	ZA 9602253	A	19960930	ZA 1996-2253	19960320
	NO 9704335	A	19971121	NO 1997-4335	19970919
PRAI	US 1995-407839		19950321		
	WO 1996-US3726		19960319		
OS	MARPAT 126:8011				
GI					



I

AB HONHCOCHR1CHR2CONR3CHR8CONR4R9 [R1 = H, alkyl, alkoxy, heterocyclyl, etc.;
 R2 = H, OH, alkyl, heterocyclyl, etc.; R1R2 = alkylene; R3 = H or (cyclo)alkyl; R4 = (cyclo)alkyl, alkoxy carbonyl(alkyl), arylsulfonyl, etc.; R8R9 = (CR2)n, CH:CH, etc.; n = 2-4] were prepd. as matrix metalloprotease inhibitors (no data). Thus, (S)-caprolactam-3-amine was amidated by (R)-Me3CO2CCH2CH(CH2CHMe2)CO2H and the product N-alkylated by BrCH2CO2Me to give, in 2 addnl. steps, title compd. I.
 IT 183665-06-7P 183665-08-9P 183665-09-0P

183665-10-3P 183665-12-5P 183665-14-7P
 183665-15-8P 183665-17-0P 183665-18-1P
 183665-19-2P 183665-20-5P 183665-21-6P
 183665-22-7P 183665-23-8P 183665-26-1P
 183665-29-4P 183665-33-0P 183901-48-6P
 183901-49-7P 183901-50-0P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn: of 3-[(hydroxaminocarbonyl)alkanamido]caprolactams and analogs as matrix metalloprotease inhibitors)

RN 183665-06-7 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-oxo-, methyl ester, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-08-9 CAPLUS

CN Butanediamide, N1-[hexahydro-1-[2-(methylamino)-2-oxoethyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA


INDEX
 NAME)

Absolute stereochemistry.




RN 183665-09-0 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-
 methyl-1-oxopentyl]amino]-2-oxo-, 1,1-dimethylethyl ester, [S-(R*,S*)]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-10-3 CAPLUS
 CN Butanediamide, N1-[hexahydro-2-oxo-1-(phenylmethyl)-1H-azepin-3-yl]-N4-
 hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183665-12-5 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-
 methyl-1-oxopentyl]amino]-2-oxo-, phenylmethyl ester, [S-(R*,S*)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-14-7 CAPLUS

CN Butanediamide,

N1-[hexahydro-2-oxo-1-[2-oxo-2-[(phenylmethyl)amino]ethyl]-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-15-8 CAPLUS

CN Butanediamide,

N1-[1-[2-(butylamino)-2-oxoethyl]hexahydro-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-17-0 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-1-oxoheptyl]amino]-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-18-1 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-19-2 CAPLUS

CN Butanediamide,

N1-[hexahydro-1-[(4-methylphenyl)sulfonyl]-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-octyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-20-5 CAPLUS

CN Butanediamide,

N1-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-N4-hydroxy-2-octyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-21-6 CAPLUS

CN Butanediarnide, N1-(1-butylhexahydro-2-oxo-1H-azepin-3-yl)-N4-hydroxy-2-octyl-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-22-7 CAPLUS


CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-23-8 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[(2R, 3S)-3-[(hydroxyamino)carbonyl]-
 2-(2-methylpropyl)-1-oxohexyl]amino]-2-oxo-, methyl ester, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-26-1 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[6-hydroxy-3-
 [(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxohexyl]amino]-2-oxo-,
 methyl ester, [3S-[3R*(2S*, 3R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183665-29-4 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[(2R)-2-[(1S)-2-(hydroxyamino)-1-
 methyl-2-oxoethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, (3S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-33-0 CAPLUS

CN Butanediamide,

N4-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-

N1-hydroxy-2-methyl-3-octyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183901-48-6 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-2-oxo-, methyl ester, [3S-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183901-49-7 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, [3S-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183901-50-0 CAPLUS

CN Butanediamide,
N4-[(3S)-hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-
N1-hydroxy-2-methyl-3-octyl-, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 183665-39-6P 183665-61-4P 183665-65-8P
 183665-71-6P 183665-83-0P 183665-89-6P
 183665-92-1P 183665-96-5P 183665-97-6P
 183666-00-4P 183666-03-7P 183901-52-2P
 183901-58-8P 183901-62-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of 3-[(hydroxaminocarbonyl)alkanamido]caprolactams and analogs
 as matrix metalloprotease inhibitors)

RN 183665-39-6 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[4-methyl-1-oxo-2-[2-oxo-2-
 [(phenylmethoxy)amino]ethyl]pentyl]amino]-2-oxo-, methyl ester,
 [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-61-4 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-2-oxo-3-[[1-oxo-2-[2-oxo-2-
 [(phenylmethoxy)amino]ethyl]heptyl]amino]-, methyl ester, [S-(R*,S*)]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-65-8 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-2-oxo-3-[[1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]decyl]amino]-, methyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-71-6 CAPLUS

CN Butanediarnide,
N1-[hexahydro-1-[(4-methylphenyl)sulfonyl]-2-oxo-1H-azepin-3-yl]-2-octyl-N4-(phenylmethoxy)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-83-0 CAPLUS

CN Butanediamide, N1-[hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-2-octyl-N4-(phenylmethoxy)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183665-89-6 CAPLUS


CN Butanediamide, N1-(1-butylhexahydro-2-oxo-1H-azepin-3-yl)-2-octyl-N4-(phenylmethoxy)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-92-1 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[4-methyl-2-[1-methyl-2-oxo-2-
 [(phenylmethoxy)amino]ethyl]-1-oxopentyl]amino]-2-oxo-, methyl ester,
 [3S-[3R*[S*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183665-96-5 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[(2R, 3S)-2-(2-methylpropyl)-1-oxo-3-
 [[(phenylmethoxy)amino]carbonyl]-5-hexenyl]amino]-2-oxo-, methyl ester,
 (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183665-97-6 CAPLUS
 CN 1H-Azepine-1-acetic acid,
 hexahydro-3-[[6-hydroxy-2-(2-methylpropyl)-1-oxo-
 3-[[(phenylmethoxy)amino]carbonyl]hexyl]amino]-2-oxo-, methyl ester,
 [3S-[3R*(2S*, 3R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183666-00-4 CAPLUS

CN 1H-Azepine-1-acetic acid, hexahydro-3-[[2-[1-methyl-2-oxo-2-[(phenylmethoxy)amino]ethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, [3S-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183666-03-7 CAPLUS


CN Butanediamide, N4-[hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-2-methyl-3-octyl-N1-(phenylmethoxy)-, [3S-[3R*(2R*,3S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry..




RN 183901-52-2 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[4-methyl-2-[1-methyl-2-oxo-2-[(phenylmethoxy)amino]ethyl]-1-oxopentyl]amino]-2-oxo-, methyl ester, [3S-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183901-58-8 CAPLUS
 CN 1H-Azepine-1-acetic acid, hexahydro-3-[[2-[1-methyl-2-oxo-2-[(phenylmethoxy)amino]ethyl]-1-oxodecyl]amino]-2-oxo-, methyl ester, [3S-[3R*[S*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183901-62-4 CAPLUS
 CN Butanediamide, N4-[hexahydro-1-(2-methoxyethyl)-2-oxo-1H-azepin-3-yl]-2-methyl-3-octyl-N1-(phenylmethoxy)-, [3S-[3R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7. ANSWER 11 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN. 1996:163897 CAPLUS

DN. 124:232270

TI Preparation of benzazepinone derivatives as collagenase inhibitors

IN Nitsuta, Masahiro; Hirayama, Ryoichi; Yamamoto, Minoru; Ikeda, Shoji

PA Kanebo Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN. CNT. 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07304770	A2	19951121	JP 1994-123193	19940511
OS	MARPAT 124:232270				
GI					



AB The title compds. I [R1 = H, morpholino, etc.] are claimed.

(4S,2'R,1''RS)-I [R1 = morpholino] (prepn. given) in vitro showed IC50 of 4 nM against collagenase.

IT 174457-77-3P 174457-78-4P 174457-79-5P

174457-80-8P 174588-31-9P 174588-32-0P

174588-33-1P 174588-34-2P 174588-35-3P


174588-36-4P 174588-37-5P 174588-38-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of benzazepinone derivs. as collagenase inhibitors)


RN 174457-77-3 CAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)




RN 174457-78-4 CAPLUS

CN Butanediamide, N1-hydroxy-3-(2-methylpropyl)-2-(4-morpholinylmethyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)




RN 174457-79-5 CAPLUS

CN Butanediamide, N1-hydroxy-3-(2-methylpropyl)-2-(phenylthio)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)



RN 174457-80-8 CAPLUS


CN Butanediamide,
2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N1-hydroxy-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)- (9CI)
(CA INDEX NAME)



RN 174588-31-9 CAPLUS

CN Butanedi-2,3-diamide, N4-hydroxy-2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-32-0 CAPLUS

CN Butanedi-2,3-diamide, N4-hydroxy-2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3R*)]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-33-1 CAPLUS

CN Butanedi-2,3-diamide, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N1-hydroxy-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3S*)]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 174588-34-2 CAPLUS

CN Butanediamide,

2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-N1-hydroxy-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-35-3 CAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-36-4 CAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-37-5 CAPLUS

CN Butanedi-2-amine, N4-hydroxy-2-(2-methylpropyl)-3-(phenylthio)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-38-6 CAPLUS

CN Butanedi-2-amine, N4-hydroxy-2-(2-methylpropyl)-3-(phenylthio)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 174457-85-3P 174457-86-4P 174457-88-6P

174588-40-0P 174588-41-1P 174588-43-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of benzazepinone derivs. as collagenase inhibitors)

RN 174457-85-3 CAPLUS

CN Butanediamide, 2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174457-86-4 CAPLUS

CN Butanediamide, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174457-88-6 CAPLUS

CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-40-0 CAPLUS

CN Butanediamide, 2-(2-methylpropyl)-3-(4-morpholinylmethyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2S*,3R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-41-1 CAPLUS

CN Butanediamide, 2-[(3,4-dihydro-2(1H)-isoquinolinyl)methyl]-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 174588-43-3 CAPLUS


CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-N4-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [4S-[4R*(2R*,3S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1996:155497 CAPLUS
 DN 124:202051
 TI Preparation of benzazepinecarboxylic acid derivative as collagenase inhibitor
 IN Nitsuta, Masahiro; Yamamoto, Minoru
 PA Kanebo Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07304746	A2	19951121	JP 1994-123192	19940511
GI					




AB The title compd. I, enantiomers, and pharmaceutically acceptable salts thereof are claimed. (2'R)-I (prepn. given) in vitro showed IC50 of 0.35 .mu.M against collagenase.
 IT **174339-81-2P 174510-41-9P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of benzazepinecarboxylic acid deriv. as collagenase inhibitor)
 RN 174339-81-2 CAPLUS
 CN 1H-2-Benzazepine-1-carboxylic acid, 2,3,4,5-tetrahydro-4-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 174510-41-9 CAPLUS

CN 1H-2-Benzazepine-1-carboxylic acid, 2,3,4,5-tetrahydro-4-[[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-oxo-, [1R-[1.alpha.,4.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 174339-83-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of benzazepinecarboxylic acid deriv. as collagenase inhibitor)

RN 174339-83-4 CAPLUS

CN 1H-2-Benzazepine-1-carboxylic acid, 2,3,4,5-tetrahydro-4-[[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]amino]-3-oxo-, [1R-[1.alpha.,4.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



~~BT~~ ANSWER 13 OF 14 CAPLUS COPYRIGHT 2001 ACS

~~BN~~ 1995:468466 CAPLUS

~~DN~~ 122:239558

~~TI~~ Preparation of tetrahydrobenzazepinone derivatives as collagenase inhibitors

~~IN~~ Inoe, Shintaro; Oota, Hideko; Nitsuta, Masahiro; Yamamoto, Minoru

~~PA~~ Kanebo Ltd, Japan

~~SO~~ Jpn. Kokai Tokkyo Koho, 12 pp.


CODEN: JKXXAF

~~DT~~ Patent

~~LA~~ Japanese

~~FAN.CNT~~ 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06145148	A2	19940524	JP 1992-326117	19921110
GI					



AB The title compds. I [R1 = H, methoxy, etc.] are prepd.

4-(S)-[3-Hydroxyaminocarbonyl-2-(R)-(2-methylpropyl)propanoyl]amino-1,2,4,5-tetrahydro-3H-2-benzazepin-3-one [(I); R1 = H] (II) was prepd. in a multiple step process starting with phthaloyl-L-phenylalaninamide. II in vitro showed IC50 of 20 nM against collagenase.

IT 162004-50-4P 162004-51-5P 162004-52-6P


162004-55-9P 162004-56-0P 162004-57-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tetrahydrobenzazepinone derivs. as collagenase inhibitors)


RN 162004-50-4 CAPLUS

CN Butanedi-
 amide, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)




RN 162004-51-5 CAPLUS

CN Butanedi-
 amide, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-8-methoxy-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)



RN 162004-52-6 CAPLUS


CN Butanedi-
 amide, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-8-hydroxy-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)



RN 162004-55-9 CAPLUS

CN Butanedi-
 amide, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-8-methoxy-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162004-56-0 CAPLUS

CN Butanedi-2-amine, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-8-methoxy-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162004-57-1 CAPLUS

CN Butanedi-2-amine, N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-8-hydroxy-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 162004-54-8P 162004-62-8P 162004-69-5P
162004-70-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tetrahydrobenzazepinone derivs. as collagenase inhibitors)


RN 162004-54-8 CAPLUS
 CN Butanediamide,
 N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-3-oxo-
 1H-2-benzazepin-4-yl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 162004-62-8 CAPLUS
 CN Butanediamide, 2-(2-methylpropyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-
 tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,S*)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 162004-69-5 CAPLUS
 CN Butanediamide, 2-(2-methylpropyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-
 tetrahydro-8-methoxy-3-oxo-1H-2-benzazepin-4-yl)- (9CI) (CA INDEX NAME)



RN 162004-70-8 CAPLUS
 CN Butanediamide, 2-(2-methylpropyl)-N4-(phenylmethoxy)-N1-(2,3,4,5-

tetrahydro-8-hydroxy-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,S*)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



IT 162004-53-7P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of tetrahydrobenzazepinone derivs. as collagenase inhibitors)

RN 162004-53-7 CAPLUS

CN Butanediamide,

N4-hydroxy-2-(2-methylpropyl)-N1-(2,3,4,5-tetrahydro-3-oxo-1H-2-benzazepin-4-yl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



~~D7~~ ANSWER 14 OF 14 CAPLUS COPYRIGHT 2001 ACS

~~AN~~ 1972:421486 CAPLUS

~~DN~~ 77:21486

~~TI~~ Fiber-forming polyamides containing an additive for improving color intensity, modulus of elasticity, and flat spotting

~~IN~~ Ottenheym, Johannes H.; Van Krimpen, Pieter C. A.; Franssen, Pierre J.

~~PA~~ Stamicarbon N. V.

~~SO~~ U.S., 2 pp.

~~DT~~ CODEN: USXXAM

~~LA~~ Patent

~~FAN~~ English

CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.


DATE

PI US 3651023 A 19720321 US 1968-741897 19680702
 AB Caprolactam (I) contg. 0.5-5% N,N'-bis(hexahydro-2-oxo-3-azepinyl)-p-xylylenediamine [35108-78-2],
 N,N'-bis(hexahydro-2-oxo-3-azepinyl)succinic acid diamide [35074-64-7], a mixt. of .alpha.-(methyleneamino)-.epsilon.-caprolactam [35074-65-8], N,N'-bis(hexahydro-2-oxo-3-azepinyl)methylenediamine [35074-66-9] and 1,3,5-tris(hexahydro-2-oxo-3-azepinyl)-s-triazine [35074-67-0], .epsilon.-N-methylenelysine [35074-17-0], .alpha.-amino-.epsilon.-caprolactam [671-42-1], or lysine [56-87-1] was spun into polyamide fibers with improved color intensity, modulus of elasticity and flat spotting. Thus, I contg. 1% lysine 0.15% HOAc, and 14.7% H2O was polymd. at 260.deg./5-6 atm. for 3 hr, the pressure was reduced to 1 atm., and heating continued an addnl. 3 hr.

The mass was extruded into filaments with 7.5-9 g/denier tensile strength, 15-17% elongation at break, 55-65 modulus of elasticity, and 1.2-1.4mm flat-spot index. A similar fiber not processed with lysine had 8.9 g/denier, 14-15%, 45-55, and 2.0-2.3mm values, resp.

IT **35074-64-7**
 RL: USES (Uses)
 (polyamide fibers modified by, for improved elasticity and resistance to flat spotting)

RN 35074-64-7 CAPLUS
 CN Butanediamide, N,N'-bis(hexahydro-2-oxo-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)



=>

Connection closed by remote host



Creation date: 07-27-2004
Indexing Officer: JPHAM - JERRY PHAM
Team: OIPEBackFileIndexing
Dossier: 09505788

Legal Date: 01-25-2001 ✓

No.	Doccode	Number of pages
1	CTNF	16
2	892	1

Total number of pages: 17

Remarks:

Order of re-scan issued on